The Frontrunners in Clinical Cytogenomics
Chromosome disorders form a major category of genetic disease. The incidence of chromosome abnormalities is relatively common in the population. In a clinical scenario, chromosome abnormalities account for a large proportion of cases involving spontaneous abortions; individuals with congenital malformations, mental retardation, or infertility; women with gonadal dysgenesis; and couples with repeated spontaneous miscarriages. Additionally, the field of cytogenetics is now important in the workup of patients with hematologic/oncologic disorders. Cytogenetic testing in this area is used for diagnosis, classification of disease, helps with decisions about treatment and to monitor disease status and recovery.
The Cytogenomics Laboratory at Dr. Lal PathLabs is a frontrunner in the field of cytogenetics. The laboratory’s technical and professional experience in diagnosing and reporting the most complex Cytogenetics and Cytogenomics results is unparalleled. Our laboratory staff are committed to providing the highest quality of cytogenetic analyses available to complement your clinical practice. We are consistently at the forefront of the development and implementation of new tests by FISH (fluorescence in situ hybridization) for congenital and hematologic/oncologic disorders.
The Cytogenomics Laboratory provides comprehensive services in all types of chromosome studies, including congenital disorders, prenatal diagnosis, and hematologic/oncologic disorders including:
- Chromosome analysis for prenatal samples, peripheral blood, bone marrow, lymphomas and solid tumors
- FISH (fluorescence in situ hybridization) assays and many probes that are available only at the LPL Cytogenomics department
- Microarray assays for congenital (pre- and postnatal) disorders
The laboratory’s ongoing mission is to continue to develop new tests and create comprehensive testing algorithms to bridge the gap(s) between Molecular Cytogenetics, Microarray Analysis and Testing by Next Generation Sequencing.
